Erythropoietin stimulating agent

Phase 2

AAin Shams University

Erythropoietin stimulating agent is one of 48 therapeutic programs targeting Anemia. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

AnemiaNot yet recruiting

AnemiaPhase 2

Not yet recruiting

Competition

Competitive Landscape

75 competitors in Anemia

#DrugCompanyPhaseTrials

Epogen

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Phase 3

52 2

Nipent

Pfizer

Approved

—3

Kenalog

BBausch Health Americas, Inc.

Rayos

Orgovyx

Sumitomo Pharma America, Inc.

Rituxan

2 7

Cytoxan

BBaxter Healthcare Corporation

Phase 3

6 8

Campath

GGenzyme, a Sanofi Company

Phase 3

2 9

Revlimid

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 3

2 10

Imbruvica

PPharmacyclics LLC.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 2Not yet recruiting

Anemia

NCT07715318

Clinical

Trials by Indication[1]

Anemia1 trial

Efficacy and Safety of Spironolactone in Pediatric Hemodialysis Patients With Anemia.

Not yet recruiting·AAin Shams University·Phase 2·NCT07715318·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Erythropoietin stimulating agent. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Erythropoietin stimulating agent. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Ain Shams University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: AAin Shams University

Erythropoietin stimulating agent

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q1 2028

Trials by Indication[1]

Anemia1 trial

References

Drug Info

Quick Facts

Related News